Bangladesh Technical Education Board

Philip R. Lane: Disinflation in the euro area: an update

Retrieved on: 
Thursday, April 18, 2024
Element, Reproduction, SAFE, Speech, Conference, Growth, Brookings Institution, Disinflation, Finance, Projection, Exercise, ECB, Real, Risk, Frankfurt, Bank, SPF, Policy, Communication, ILS, HICP, OIS, DFR, GDP, The, APP, Watcher, Bangladesh Technical Education Board, Probability, Swings, Fiscal, Acceleration, Goethe University Frankfurt, Personal ordinariate, PEPP, CTS, European Central Bank, Fear, Bookkeeping

Stock market development and familiarity (language and distance) are considered key determinants for home bias.

Key Points: 
  • Stock market development and familiarity (language and distance) are considered key determinants for home bias.
  • The literature neglects however that investors often invest in foreign funds domiciled in financial centers.

ADS-TEC Energy Announces New Board Appointment

Retrieved on: 
Wednesday, April 10, 2024
Government, European Institute, University, Partner, Freshfields Bruckhaus Deringer, Economics, Bangladesh Technical Education Board

NÜRTINGEN, Germany – March 14, 2024 – ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, is very pleased to announce the appointment of Dr. Andreas Fabritius to its Board of Directors.

Key Points: 
  • NÜRTINGEN, Germany – March 14, 2024 – ADS-TEC Energy plc (“ADS-TEC Energy”, “Company”, “we”, “our” or “us”) (NASDAQ: ADSE), a global leader in battery-buffered, ultra-fast charging technology, is very pleased to announce the appointment of Dr. Andreas Fabritius to its Board of Directors.
  • “We are delighted to announce that Dr. Andreas Fabritius has joined our Board of Directors,” stated Dr. Kurt Lauk, Chairman of the Board of Directors.
  • “With a strong track record as an international lawyer, he will strengthen our Board in our high growth market and further improve our ability to provide shareholder value.
  • His extensive international experience and high professional standing compliments our Board in the best possible way.”
    “I am delighted to join the Board of Directors of ADS-TEC Energy.

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, NIHCC, FLA, NIH, Male, Urinary incontinence, Erectile dysfunction, CLS, Bangladesh Technical Education Board, Medical imaging

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • “This second order of our TRANBERG Focal Laser Ablation accessories enables our continued collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Retrieved on: 
Monday, April 8, 2024
JHU, NCI, Development, Carcinoma, CRADA, National Cancer Institute, MSKCC, IND, Investigational New Drug, Genomics, Immune system, Bangladesh Technical Education Board, FDA, SCLC, Food, Pharmaceutical industry

This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.

Key Points: 
  • This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.
  • The trial ( NCT06287775 ) is entitled “A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer”.
  • “We are very pleased that NCI has received the regulatory approval from the FDA to initiate this first-in-human Phase I/II combination trial with iadademstat plus immune check point inhibitors” stated Dr. Carlos Buesa, Chief Executive Officer of Oryzon.
  • “The molecular mechanisms underlying the ability of iadademstat to render small cell lung cancer cells visible to the immune system while simultaneously enhancing immune activity to aggressively target these malignant cells have been clearly elucidated.

LIS Technologies Inc. Establishes Corporate Affiliation with the Nuclear Institute

Retrieved on: 
Friday, April 5, 2024
Uranium, Nuclear, Isotope, Environment, Patent, Science, Engineering, Society, LIS, Science Council, Nuclear Institute, Engineering Council, Bangladesh Technical Education Board, Renewable energy

“It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.

Key Points: 
  • “It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.
  • Additionally, through its numerous events, seminars, and volunteer-led activities, the Nuclear Institute ensures a robust platform for professional interaction and development within the nuclear sector.
  • “We are delighted to welcome LIS Technologies Inc as a Corporate Affiliate of the Nuclear Institute,” said Sarah Beacock, Chief Executive Officer of the Nuclear Institute.
  • “As a proprietary developer of patented advanced laser technology based in the US, LIS Technologies are showing their commitment to advancing nuclear science and technology.

Fraser Institute News Release: Flat 8 per cent personal income tax would save Albertans $1,573 a year, on average

Retrieved on: 
Wednesday, April 3, 2024
Research, Bangladesh Technical Education Board, Fraser Institute, PIT, Public policy, Government, Work, Entrepreneurship, Life insurance

As recently as 2014, Alberta had a single 10 per cent personal and corporate income tax rate.

Key Points: 
  • As recently as 2014, Alberta had a single 10 per cent personal and corporate income tax rate.
  • As a result, it had the lowest top statutory combined federal and provincial/state personal income tax rate and business income tax rate in North America.
  • While the business tax rate has since been reduced to eight per cent, the personal income tax rate increases remain.
  • “Rolling back the 2015 personal income tax increases and implementing an eight per cent flat personal income tax rate would help restore Alberta’s tax competitiveness and keep more money in the pockets of Albertans,” Hill said.

BioCorRx Reports Business Update for 2023

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Substance abuse, Bupropion, CFO, Risk, Public, OUD, Research, Security (finance), Opioid use disorder, NIH, Naltrexone, Bangladesh Technical Education Board, MUD, OTCQB, Pharmaceutical industry

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD).
  • We successfully decreased our total operating expenses by over $1.0 million for the year ending December 31, 2023, compared to the previous year.
  • Overall, we are optimistic about the business outlook and look forward to continuing to develop medicines.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Monday, April 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).